Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

NCT02223247 is registered in ClinicalTrials.gov with Sagimet Biosciences Inc. as lead sponsor.

NCT NCT02223247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02223247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors
Lead sponsor
Sagimet Biosciences Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2013
Completion date
June 30, 2017
Enrollment
180 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

solid malignant tumor